Novel treatment strategies investigated for thymic epithelial tumours lead to uncertain benefits
Rivoceranib after prior therapy and peri-operative pembrolizumab demonstrates promising efficacy but it is not superior to the current standard therapy
Immunotherapy combinations enhance radiotherapy response in resectable sarcoma
Effective biomarkers and histology-focused enrichment trials are now needed to further improve patient outcomes
First-line ivonescimab plus chemotherapy improves progression-free survival in squamous NSCLC
Robust efficacy findings and unexpectedly low haemorrhagic events were observed with the bispecific antibody but results will only change practice if benefits translate into overall survival and are replicated beyond China
How can regular exercise be integrated into the patient journey?
Although the benefits of exercise in patients with cancer are now well established, barriers to an effective integration of physical activity into cancer care remain
Novel KRAS G12C and G12D inhibitors show early signs of activity in advanced solid tumours
As it emerges from some studies presented across different cancers, toxicity remains a major challenge
Dose-dense paclitaxel and novel combination maintenance therapies offer survival benefits in advanced ovarian cancer
Positive results are reported from the FZOCUS-1 and ICON8B studies
How therapeutically tractable is MUC1 as a tumour-associated antigen?
Early proof-of-concept is provided showing pan-tumour activity of a novel antibody–drug conjugate
Personalised cancer vaccines: the next frontier or an elusive goal?
Although genomics-guided personalised cancer vaccines have demonstrated efficacy in early-phase clinical studies, we are still awaiting the results of larger-scale trials
How connecting the dots could deliver a breakthrough in cancer vaccines
After decades of missed promises, cancer vaccines are likely approaching prime time due to major advances in cancer immunobiology, immunotherapy and biomedical technology
Is there a role for GLP-1 in the prevention and treatment of cancer?
Interest is growing rapidly in the field of oncology in the anti-obesity drug target that has recently been investigated in large retrospective studies and preclinical models